Leo Pharma has filed an application for marketing authorization of tralokinumab, the company’s treatment for patients with moderate-to-severe atopic eczema, in Japan, the company announces in a press release.
The filing with the Japanese Pharmaceutical and Medical Devices Agency (PMDA) comes one month after Leo Pharma was successful in finally getting tralokinumab approved by the US Food and Drug Administration (FDA), a verdict that had been postponed by eight months.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.